TrialSignal
Clinical trial intelligence report
A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04555486
Status
COMPLETED
Phase
PHASE1
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Executive brief
Investment-Ready Snapshot
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04555486
Indication
Primary Hyperoxaluria Type 3
Modality
small molecule
Target
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Intervention
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.